Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021

被引：3

作者：

Glover, Michael ^{[1
]}

Hui, Gavin ^{[1
]}

Chiang, Ryan ^{[1
]}

Savage, Philip ^{[2
]}

Krell, Jonathan ^{[3
]}

Julve, Maximilian ^{[3
]}

Grivas, Petros ^{[4
]}

Lythgoe, Mark ^{[3
]}

Khaki, Ali Raza ^{[5
]}

机构：

[1] Stanford Univ, Dept Med, Stanford, CA 94305 USA

[2] Brighton & Sussex Univ Hosp NHS Trust, Dept Oncol, Brighton, E Sussex, England

[3] Hammersmith Hosp, Imperial Coll London, Dept Surg & Canc, London, England

[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Med Oncol,Clin Res Div, Seattle, WA USA

[5] Stanford Univ, Dept Med, Div Oncol, Stanford, CA USA

来源：

BJU INTERNATIONAL | 2022年 / 129卷 / 02期

关键词：

D O I：

10.1111/bju.15629

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：168 / 170

页数：3

共 50 条

[21] Reporting Cosmetic Adverse Events to the US Food and Drug Administration
Katz, Linda M.
Valenzuela, Claudia
Sadrieh, Nakissa K.
DERMATITIS, 2016, 27 (04) : 236 - 237
[22] An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021
Li, Xiaotong
Ndungu, Patrick
Taneja, Sanya B.
Chapin, Maryann R.
Egbert, Susan B.
Akenapalli, Krishi
Paine, Mary F.
Kane-Gill, Sandra L.
Boyce, Richard D.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (06): : 1002 - 1011
[23] Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
Wang, Jun
Zou, Dongna
Li, Yuchao
Liu, Pingping
Guo, Chenyu
FRONTIERS IN PHARMACOLOGY, 2023, 14
[24] Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021
Kandemir, Esin Aysel
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 191 - 207
[25] Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in US Food and Drug Administration Drug Approvals From 2000 to 2020
Berkowitz, Sean T.
Groth, Sylvia L.
Gangaputra, Sapna
Patel, Shriji
JAMA OPHTHALMOLOGY, 2021, 139 (06) : 629 - 637
[26] The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020
Gloy, Viktoria
Schmitt, Andreas M.
Dueblin, Pascal
Hirt, Julian
Axfors, Cathrin
Kuk, Hanna
Pereira, Tiago V.
Locher, Clara
Caquelin, Laura
Walter-Claudi, Martin
Lythgoe, Mark P.
Herbrand, Amanda
Kasenda, Benjamin
Hemkens, Lars G.
INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (12) : 2474 - 2484
[27] POLICY DEBATE: The US food and drug administration and new drug approvals: A safety vs. innovation paradox?
Hemphill, Thomas A.
INNOVATION-MANAGEMENT POLICY & PRACTICE, 2013, 15 (03): : 364 - 367
[28] Vitiligo adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021
Learned, Christine
Cohen, Stephanie R.
Alsukait, Sarah
Deverapalli, Sandhya
Rosmarin, David
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : 197 - 199
[29] Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
Mitra-Majumdar, Mayookha
Gunter, Simon J.
Kesselheim, Aaron S.
Brown, Beatrice L.
Joyce, Krysten W.
Ross, Murray
Pham, Catherine
Avorn, Jerry
Darrow, Jonathan J.
JAMA NETWORK OPEN, 2022, 5 (05)
[30] New US Food and Drug Administration Approvals Decrease Generic Flucytosine Costs Reply
Jarvis, Joseph N.
Harrison, Thomas S.
CLINICAL INFECTIOUS DISEASES, 2019, 69 (04) : 732 - 735

← 1 2 3 4 5 →